Abstract
Reanalysis of inconclusive exome/genome sequencing data increases the diagnosis yield of patients with rare diseases. However, the cost and efforts required for reanalysis prevent its routine implementation in research and clinical environments. The Solve-RD project aims to reveal the molecular causes underlying undiagnosed rare diseases. One of the goals is to implement innovative approaches to reanalyse the exomes and genomes from thousands of well-studied undiagnosed cases. The raw genomic data is submitted to Solve-RD through the RD-Connect Genome-Phenome Analysis Platform (GPAP) together with standardised phenotypic and pedigree data. We have developed a programmatic workflow to reanalyse genome-phenome data. It uses the RD-Connect GPAP’s Application Programming Interface (API) and relies on the big-data technologies upon which the system is built. We have applied the workflow to prioritise rare known pathogenic variants from 4411 undiagnosed cases. The queries returned an average of 1.45 variants per case, which first were evaluated in bulk by a panel of disease experts and afterwards specifically by the submitter of each case. A total of 120 index cases (21.2% of prioritised cases, 2.7% of all exome/genome-negative samples) have already been solved, with others being under investigation. The implementation of solutions as the one described here provide the technical framework to enable periodic case-level data re-evaluation in clinical settings, as recommended by the American College of Medical Genetics.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | European Journal of Human Genetics |
| Jahrgang | 29 |
| Ausgabenummer | 9 |
| Seiten (von - bis) | 1337-1347 |
| Seitenumfang | 11 |
| ISSN | 1018-4813 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 01.09.2021 |
Fördermittel
Funding The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. Data were analysed using the RD‐ Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies. We acknowledge support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d’Empresa i Coneixement and the Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program.
| Träger | Trägernummer |
|---|---|
| Ministerio de Economía y Competitividad | |
| European Commission | |
| Instituto de Salud Carlos III | PT17/0009/0019, PT13/0001/0044 |
| European Molecular Biology Laboratory | |
| Horizon 2020 Framework Programme | 825575, 779257, 305444 |
| Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España | |
| European Regional Development Fund | |
| Medical Research Council | MR/S002065/1 |
| EJP-RD | H2020 779257, H2020 825575, FP7 305444 |
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
Strategische Forschungsbereiche und Zentren
- Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)
- Zentren: Zentrum für Seltene Erkrankungen (ZSE)
- Querschnittsbereich: Medizinische Genetik
DFG-Fachsystematik
- 2.23-07 Klinische Neurologie, Neurochirurgie und Neuroradiologie
- 2.23-06 Molekulare und zelluläre Neurologie und Neuropathologie
Fingerprint
Untersuchen Sie die Forschungsthemen von „Solving patients with rare diseases through programmatic reanalysis of genome-phenome data“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver